

BAUSCH + LOMB

Trulign Toric

Accommodating Posterior Chamber Intraocular Lens**PHYSICIAN LABELING****DEVICE DESCRIPTION**

The Bausch + Lomb Trulign Toric Accommodating Posterior Chamber Intraocular Lens is a modified plate haptic lens with hinges across the plates adjacent to the optic. Trulign Toric lens Models AT50T/AT52T have a spherical front (anterior) surface with alignment marks and a toric back (posterior) surface. Trulign Toric lens Models BL1AT/BL2AT and BL1UT/BL2UT have an aspheric front (anterior) surface with alignment marks and an aspheric toric back (posterior) surface.

The available powers are 4.0 to 33.0 diopters in 0.50 diopter increments with a cylindrical power of 1.25 to 2.75 diopters in the long axis of the lens in 0.75 diopter increments.

The physical characteristics of the Trulign Accommodating Posterior Chamber Intraocular Lens are described in Table 1.

TABLE 1:
PHYSICAL CHARACTERISTICS OF TRULIGN TORIC ACCOMMODATING POSTERIOR CHAMBER
INTRAOCULAR LENS

Feature	AT50T1 to T3	AT52T1 to T3	BL1AT1 to T3	BL2AT1 to T3	BL1UT1 to T3	BL2UT1 to T3
Overall Diameter	11.5mm	12.0mm	11.5mm	12.0mm	11.5mm	12.0mm
Material Body & Plates	Silicone				UVAM (Silicone with enhanced UV-absorber)	
Optic Diameter	5.0 mm					
Plate Overall	10.5mm					
Plate Configuration	Rectangular					
Anterior Surface	Spherical with Axis-mark		Aspheric with Axis-mark			
Posterior Surface	Toric (CYL at 1.25, 2.00, 2.75 D)		Aspherized Toric (CYL at 1.25, 2.00, 2.75 D)			
Loop (haptic) material	Polyimide					
Index of Refraction at 546nm	1.4301					

INDICATIONS FOR USE

The Trulign Toric posterior chamber intraocular lens is intended for primary implantation in the capsular bag of the eye for visual correction of aphakia and postoperative refractive astigmatism secondary to removal of a cataractous lens in adult patients with or without presbyopia, who desire improved uncorrected distance vision and reduction of residual refractive cylinder. Trulign Toric provides approximately one diopter of monocular accommodation which allows for near, intermediate, and distance vision without spectacles.

WARNINGS

1. Some patients may still require glasses to perform certain tasks.
2. There is no clinical data to support placing this lens in the ciliary sulcus.
3. The safety and effectiveness of this lens have not been evaluated in patients under 50 years of age.
4. Before implantation of the Trulign Toric IOL, surgeons should verify that the cornea is appropriately marked for the steep axis.
5. Rotation of Toric lenses away from their intended axis can reduce their effectiveness. Misalignment can increase postoperative refractive cylinder. Repositioning of this lens to the intended axis should only be performed when a significant reduction in effectiveness of the Trulign Toric is noticed. This lens should only be repositioned when the refractive needs of the patient outweigh the potential risks inherent in any surgical reintervention into the eye.
6. The effect of vitrectomy on accommodation is unknown.
7. Small amounts of lens decentration occurring with an IOL having a narrow or small optic (< 5.5 mm) may cause glare or other visual disturbances under certain lighting conditions. Surgeons should consider this potential complication before implanting an IOL with a small or narrow optic. This lens incorporates a 5.0 mm optic.
8. YAG-laser posterior capsulotomies should be delayed until at least 12 weeks after the implant surgery. The posterior capsulotomy opening should be limited to no more than 4 mm. Consistent with other IOLs, there is an increased risk of lens dislocation and/or secondary surgical re-intervention with early or large YAG capsulotomies.
9. The Trulign should not be implanted if the capsular bag is not intact or if there is any zonular rupture.
10. The safety and effectiveness of the device has not been established in patients with the following ocular conditions:
 1. Chronic drug miosis
 2. Amblyopia
 3. Diabetic retinopathy
 4. Previous corneal transplant
 5. History of retinal detachment
 6. Congenital bilateral cataracts
 7. Recurrent anterior or posterior segment inflammation of unknown etiology, or any disease producing an inflammatory reaction in the eye.
 8. Patients in whom the intraocular lens may interfere with the ability to observe, diagnose or treat posterior segment diseases.
 9. Surgical difficulties at the time of intraocular lens implantation which might increase the potential for complications (e.g., persistent bleeding, significant vitreous prolapse or loss).
 10. Corneal endothelial dystrophy.
 11. Pseudoexfoliation syndrome.
 12. Suspected microbial infection.
11. Surgeons considering lens implantation in such patients should explore the potential risk/benefit ratio.
12. Mechanical hinge testing has been evaluated in a laboratory setting.
13. Hinge movements of 1,000,000 cycles at 10 cycles per second have been documented with no degradation of hinge integrity or stability. However, long-term stability in the human eye has not been established. Therefore, surgeons should continue to monitor implant patients postoperatively on a regular basis.
14. The effectiveness of ultraviolet light absorbing lenses in reducing the incidence of retinal disorders has not been established.
15. The rate of cystoid macular edema may increase with sulcus-bag placement of the haptics.

PRECAUTIONS

1. **The potential for the lens to rotate causing misalignments that will reduce the effectiveness of the Trulign Toric may be greater in some eyes.**
2. **Lens rotation less than 5° may not warrant reorientation.**
 3. Do not resterilize this intraocular lens by any method (See Returned Lens Policy).
 4. Do not store lenses at temperatures over 45°C (113°F).
 5. Do not implant this lens in the anterior chamber.
 6. The Trulign will center automatically at the end of surgery. The optic should be vaulted backward to a position corresponding to the normal location of the posterior capsule. **Attempts to position the lens further posteriorly by hyper-inflating the globe with BSS could lead to hyperopic outcomes and should be avoided.**
 7. **A wound leak could cause forward vaulting of the optic.** Therefore a scleral tunnel or long multiplane limbal/corneal incision is recommended with a long narrow paracentesis. These incisions are less likely to require suturing, which could cause astigmatism and reduce the postoperative uncorrected vision.

ADVERSE EVENTS

The incidence of adverse events experienced during the clinical trial was comparable to or lower than the incidence reported in the historic control ("FDA grid") population (see Table 11-12). As with any surgical procedure, risk is involved. Potential adverse events accompanying cataract or implant surgery may include, but are not limited to, the following: lens subluxation, corneal endothelial damage, non-pigment precipitates, cystoid macular edema, infection (endophthalmitis), retinal detachment, vitreous loss, pupillary block, corneal edema, hypopyon, secondary glaucoma, iris prolapse, vitreous-wick syndrome, uveitis, secondary surgical intervention and pupillary membrane. Secondary surgical interventions include, but are not limited to: lens repositioning, lens replacement, vitreous aspirations or iridectomy for pupillary block, wound leak repair and retinal detachment repair.

CLINICAL TRIAL (TRULIGN TORIC)

The US clinical trial of the Trulign Toric Accommodating Posterior Chamber Intraocular Lens was conducted in 229 eyes of 229 patients (227 eyes in 227 patients were implanted). The dioptric power range was 16.0 to 16.5 for the AT-52T and 17.0 to 27.0 D for the AT-50T with cylindrical powers at the lens plane of 1.25 D, 2.00 D and 2.75 D.

RESULTS

The results achieved by 227 patients followed postoperatively for six months provide data to support the conclusion that eyes implanted with a Trulign Toric following cataract extraction achieve visual correction of aphakia and astigmatism. The data support a percent reduction in absolute cylinder, rotational stability of the lens, and improvement of uncorrected visual acuity at distance following implantation of Trulign Toric.

The percent reduction of cylinder within 0.50D and 1.00D of intended correction for the Trulign Toric Accommodating Posterior Chamber Intraocular Lens was 78.4% and 95.5%, respectively. The results are shown in **Table 1**.

Preservation of best-corrected visual acuity show 98.0% and 100.0% of eyes implanted with a Toric lens reported a VA of 20/40 or better at six months at Distance and Near, respectively. All visual acuity results are presented in **Tables 2-10**.

The rotational stability of the Toric lens was demonstrated in a cohort of patients across the Form 3 to Form 4 (1-2 months to 3-6 months) postoperative intervals. A total of 100% (122/122 eyes) of subjects demonstrated less than or equal to 5 degrees of rotation between Consecutive Visits. Additionally, 96.1% of eyes exhibited rotation of less than or equal to 5 degrees between the day of surgery and the Form 4 visit, demonstrating rotational stability in the early postoperative period. The results are shown in **Table 13**.

No eyes (0%, 0/20) in the highest available cylinder correction (2.75D) reported significant visual disturbances through Form 4. The results are shown in **Table 14**.

TABLE 1
PERCENT OF EYES WITH REDUCTION IN CYLINDER WITHIN 0.50 D AND 1.00 D OF INTENDED – FORM 4 (EFFECTIVENESS)

	Control IOL (N=72)	Toric IOL 1.25 D (N=75)	Toric IOL 2.00 D (N=40)	Toric IOL 2.75 D (N=23)	All Toric IOL (N=138)
Total Non-Missing	68	74	39	21	134
Within 0.50 D of Intended	30 (44.1%)	59 (79.7%)	31 (79.5%)	15 (71.4%)	105 (78.4%)
Within 1.00 D of Intended	49 (72.1%)	71 (95.9%)	36 (92.3%)	21 (100.0%)	128 (95.5%)

TABLE 2
PRESERVATION OF BCDVA AT EACH EXAMINATION (ALL TORIC IOLS, IMPLANTED SAFETY SUBJECTS)

	Preop	Form 3	Form 4	Form 5	Form 6	Unscheduled
20/40 or Better	108 (72.0%)	143 (99.3%)	144 (98.0%)	143 (98.6%)	141 (98.6%)	39 (97.5%)
Worse than 20/40	42 (28.0%)	1 (0.7%)	3 (2.0%)	2 (1.4%)	2 (1.4%)	1 (2.5%)

TABLE 3
PRESERVATION OF BCNVA AT EACH EXAMINATION (ALL TORIC IOLS, IMPLANTED SAFETY SUBJECTS)

	Preop	Form 3	Form 4	Form 5	Form 6	Unscheduled
20/40 or Better	124 (89.2%)	141 (98.6%)	147 (100.0%)	142 (98.6%)	142 (99.3%)	30 (100.0%)
Worse than 20/40	15 (10.8%)	2 (1.4%)	0	2 (1.4%)	1 (0.7%)	0

TABLE 4
DCIVA AT 32 INCHES (80 CM) – FORM 4 (EFFECTIVENESS)

	Control IOL (N=72)	Toric IOL 1.25 D (N=75)	Toric IOL 2.00 D (N=40)	Toric IOL 2.75 D (N=23)	All Toric IOL (N=138)
DCIVA (logMAR)					
Total Non-Missing	67	74	38	21	133
Mean (SD)	0.074 (0.142)	0.060 (0.107)	0.059 (0.149)	0.024 (0.139)	0.054 (0.125)
DCIVA (Snellen)					
20/40 or Better	64 (95.5%)	74 (100.0%)	38 (100.0%)	21 (100.0%)	133 (100.0%)
Worse than 20/41	3 (4.5%)	0	0	0	0

TABLE 5
DCNVA AT 16 INCHES (40 CM) – FORM 4 (EFFECTIVENESS)

	Control IOL (N=72)	Toric IOL 1.25 D (N=75)	Toric IOL 2.00 D (N=40)	Toric IOL 2.75 D (N=23)	All Toric IOL (N=138)
DCNVA (logMAR)					
Total Non-Missing	67	74	38	21	133
Mean (SD)	0.309 (0.138)	0.308 (0.130)	0.310 (0.154)	0.258 (0.172)	0.301 (0.144)
DCNVA (Snellen)					
20/40 or Better	42 (62.7%)	47 (63.5%)	22 (57.9%)	16 (76.2%)	85 (63.9%)
Worse than 20/41	25 (37.3%)	27 (36.5%)	16 (42.1%)	5 (23.8%)	48 (36.1%)

TABLE 6
DCNVA AT 16 INCHES (40 CM) WITH ADD – FORM 4 (EFFECTIVENESS)

	Control IOL (N=72)	Toric IOL 1.25 D (N=75)	Toric IOL 2.00 D (N=40)	Toric IOL 2.75 D (N=23)	All Toric IOL (N=138)
DCNVA with Add (logMAR)					
Total Non-Missing	68	74	39	21	134
Mean (SD)	0.045 (0.072)	0.039 (0.075)	0.031 (0.066)	0.038 (0.074)	0.036 (0.072)
DCNVA with Add (Snellen)					
20/40 or Better	68 (100.0%)	74 (100.0%)	39 (100.0%)	21 (100.0%)	134 (100.0%)
Add (D)					
Mean (SD)	1.599 (0.575)	1.473 (0.451)	1.423 (0.494)	1.405 (0.599)	1.448 (0.486)

TABLE 7
BCDVA WITHOUT GLARE – FORM 4 (EFFECTIVENESS)

	Control IOL (N=72)	Toric IOL 1.25 D (N=75)	Toric IOL 2.00 D (N=40)	Toric IOL 2.75 D (N=23)	All Toric IOL (N=138)
BCDVA (logMAR)					
Total Non-Missing	68	74	39	21	134
Mean (SD)	0.012 (0.094)	0.003 (0.073)	-0.003 (0.076)	0.019 (0.180)	0.004 (0.097)
BCDVA (Snellen)					
20/40 or Better	68 (100.0%)	74 (100.0%)	39 (100.0%)	20 (95.2%)	133 (99.3%)
Worse than 20/41	0	0	0	1 (4.8%)	1 (0.7%)

TABLE 8
UCDVA – FORM 4 (EFFECTIVENESS)

	Control IOL (N=72)	Toric IOL 1.25 D (N=75)	Toric IOL 2.00 D (N=40)	Toric IOL 2.75 D (N=23)	All Toric IOL (N=138)
UCDVA (logMAR)					
Total Non-Missing	68	74	39	21	134
Mean (SD)	0.189 (0.181)	0.099 (0.140)	0.082 (0.119)	0.091 (0.130)	0.093 (0.132)
UCDVA (Snellen)					
20/40 or Better	51 (75.0%)	71 (95.9%)	39 (100.0%)	21 (100.0%)	131 (97.8%)
Worse than 20/41	17 (25.0%)	3 (4.1%)	0	0	3 (2.2%)

TABLE 9
UCIVA – FORM 4 (EFFECTIVENESS)

	Control IOL (N=72)	Toric IOL 1.25 D (N=75)	Toric IOL 2.00 D (N=40)	Toric IOL 2.75 D (N=23)	All Toric IOL (N=138)
UCIVA (logMAR)					
Total Non-Missing	68	74	39	21	134
Mean (SD)	0.069 (0.153)	0.044 (0.116)	0.058 (0.155)	0.004 (0.117)	0.042 (0.129)
UCIVA (Snellen)					
20/40 or Better	64 (94.1%)	73 (98.6%)	37 (94.9%)	21 (100.0%)	131 (97.8%)
Worse than 20/41	4 (5.9%)	1 (1.4%)	2 (5.1%)	0	3 (2.2%)

TABLE 10
UCNVA – FORM 4 (EFFECTIVENESS)

	Control IOL (N=72)	Toric IOL 1.25 D (N=75)	Toric IOL 2.00 D (N=40)	Toric IOL 2.75 D (N=23)	All Toric IOL (N=138)
UCNVA (logMAR)					
Total Non-Missing	68	74	39	21	134
Mean (SD)	0.286 (0.137)	0.284 (0.155)	0.310 (0.142)	0.268 (0.149)	0.289 (0.150)
UCNVA (Snellen)					
20/40 or Better	49 (72.1%)	53 (71.6%)	24 (61.5%)	17 (81.0%)	94 (70.1%)
Worse than 20/41	19 (27.9%)	21 (28.4%)	15 (38.5%)	4 (19.0%)	40 (29.9%)

TABLE 11
FDA GRID ADVERSE EVENTS REPORTED AT EACH POSTOPERATIVE VISIT, IMPLANTED SUBJECTS (SAFETY, CONTROL IOL)

Adverse Event	Unscheduled n/N (%)	Form 1 n/N (%)	Form 2 n/N (%)	Form 3 n/N (%)	Form 4 n/N (%)	Form 5 n/N (%)	Form 6 n/N (%)	Cumulative n/N (%)	FDA grid (%)	p-value
Cumulative										
Endophthalmitis	0/44	0/76	0/75	0/74	0/72	0/70	0/69	0/76	0.1	>0.999
Hypopyon	0/44	0/76	0/75	0/74	0/72	0/70	0/69	0/76	0.3	>0.999
Lens Dislocated From Posterior Chamber	0/44	0/76	0/75	0/74	0/72	0/70	0/69	0/76	0.1	>0.999
Macular Edema	0/44	0/76	0/75	1/74 (1.4)	1/73 (1.4)	0/70	0/69	1/76 (1.3)	3.0	0.901
Pupillary Block	0/44	0/76	0/75	0/74	0/72	0/70	0/69	0/76	0.1	>0.999
Retinal Detachment	0/44	0/76	0/75	0/74	0/72	0/70	0/69	0/76	0.3	>0.999
Secondary Surgical Intervention	0/44	0/76	1/75 (1.3)	0/74	0/72	1/70 (1.4)	0/69	2*/76 (2.6)	0.8	0.124
Persistent										
Corneal Edema								0/69	0.3	>0.999
Iritis								0/69	0.3	>0.999
Macular Edema								0/69	0.5	>0.999
Raised IOP Requiring Treatment								0/69	0.4	>0.999
*Reason for SSI: 1) IOL reposition due to IOL malposition; 2) IOL Exchange.										

TABLE 12
FDA GRID ADVERSE EVENTS REPORTED AT EACH POSTOPERATIVE VISIT, IMPLANTED SUBJECTS (SAFETY, ALL TORIC IOL)

Adverse Event	Unscheduled n/N (%)	Form 1 n/N (%)	Form 2 n/N (%)	Form 3 n/N (%)	Form 4 n/N (%)	Form 5 n/N (%)	Form 6 n/N (%)	Cumulative n/N (%)	FDA grid (%)	p-value
Cumulative										
Endophthalmitis	0/77	0/151	0/148	0/145	0/147	0/145	0/143	0/151	0.1	>0.999
Hypopyon	0/77	0/151	0/148	0/145	0/147	0/145	0/143	0/151	0.3	>0.999
Lens Dislocated From Posterior Chamber	0/77	0/151	0/148	0/145	0/147	0/145	0/143	0/151	0.1	>0.999
Macular Edema	0/77	0/151	0/148	1/145 (0.7)	1/147 (0.7)	0/145	0/143	1/151 (0.7)	3.0	0.990
Pupillary Block	0/77	0/151	0/148	0/145	0/147	0/145	0/143	0/151	0.1	>0.999
Retinal Detachment	0/77	0/151	0/148	0/145	0/147	0/145	0/143	0/151	0.3	>0.999
Secondary Surgical Intervention	0/77	0/151	0/148	0/145	1/147 (0.7)	0/145	0/143	1*/151 (0.7)	0.8	0.703
Persistent										
Corneal Edema								0/143	0.3	>0.999
Iritis								0/143	0.3	>0.999
Macular Edema								0/143	0.5	>0.999
Raised IOP Requiring Treatment								0/143	0.4	>0.999
*Reason for SSI: Reposition of IOL (2.00 D Cohort) not related to lens axis misalignment or rotation.										

TABLE 13
ROTATIONAL STABILITY BETWEEN CONSECUTIVE VISITS – FORM 4 (CONSISTENT)

	Toric IOL 1.25 D (N=69)	Toric IOL 2.00 D (N=34)	Toric IOL 2.75 D (N=19)	All Toric IOL (N=122)
Absolute Value of Rotation (°)				
Total Non-Missing	69	34	19	122
Mean (SD)	1.074 (0.966)	1.166 (0.906)	1.537 (1.406)	1.172 (1.034)
Lenses Rotating ≤5° Since Last Visit	69 (100.0%)	34 (100.0%)	19 (100.0%)	122 (100.0%)

TABLE 14
SUBJECTS EXPERIENCING ONE OR MORE SIGNIFICANT VISUAL DISTURBANCES – FORM 4 (EFFECTIVENESS, SUBJECTS WHOSE LENS WAS NOT REPOSITIONED)

	Control IOL (N=72) n(%)	Toric IOL 1.25 D (N=75) n(%)	Toric IOL 2.00 D (N=40) n(%)	Toric IOL 2.75 D (N=23) n(%)	All Toric IOL (N=138) n(%)
Total Non-Missing	66	74	39	20	133
Significant Visual Disturbance	6 (9.1)	0	1 (2.6)	0	1 (0.8)
No Significant Visual Disturbance	60 (90.9)	74 (100.0)	38 (97.4)	20 (100.0)	132 (99.2)

CLINICAL TRIAL (PARENT MODEL AT-45)

The US clinical trial of the Crystalens® Model AT-45 was conducted in 497 eyes of 324 patients. The range of axial lengths studied in the clinical trial of the Crystalens® was 21.0 to 26.6 mm and the dioptric power range was 16.5 to 27.5 D. The clinical results were obtained using an 'A' Constant of 119.0, the SRK/T formula, immersion biometry or interferometry and manual keratometry.

RESULTS

The results achieved by 304 patients followed for one year provide the data that were used to support the conclusion that postoperatively, the majority of patients implanted with this lens achieve excellent near, intermediate, and distance vision without spectacles. Visual acuity with or without correction at all distances improves when both eyes are implanted with a Crystalens.®

1. In 124 bilaterally-implanted patients, the portion of patients achieving uncorrected visual acuities of 20/32 (J2) or better at one year was:	
Distance	97.6%
Intermediate	100% at 80cm
Near	93.5% at 40 cm
2. In 74 bilaterally-implanted patients who were within $\pm 0.5D$ of plano in each eye, the portion of patients achieving uncorrected visual acuities of 20/32 (J2) or better at one year was:	
Distance	100%
Intermediate	100% at 80cm
Near	97.3% at 40 cm

The visual acuity and patient survey results are presented in **Table 16-24**.

The stability of the outcomes was demonstrated in a consistent cohort of patients across the Form 3 to Form 4 (1-2 months to 3-6 months) and Form 4 to Form 5 (3-6 months to 11-15- months) postoperative intervals. Stability was measured using both the manifest spherical equivalent (MRSE) and visual acuity.

In a substudy comparing the Crystalens® with a control population comprised of several models of standard IOLs of varying types (e.g., single piece, multipiece) and materials (e.g., silicone, acrylic), the visual acuity at all distances at 3-6 months postoperative was significantly greater in Crystalens® implanted eyes than in eyes implanted with a standard IOL. The results are shown in **Table 15**.

TABLE 15
CRYSTALENS® VS STANDARD IOL VISUAL ACUITY
(BEST SPECTACLE CORRECTED DISTANCE AND NEAR AND INTERMEDIATE
ACUITY THROUGH THE DISTANCE CORRECTION)

	CRYSTALENS®		STANDARD IOL	
20/20 or better	1/121	0.8%	0/64	0.0%
20/25 or better	29/121	24.0%	0/64	0.0%
20/32 or better	61/121	50.4%	3/64	4.7%
20/40 or better	107/121	88.4%	23/64	35.9%
Worse than 20/40	14/121	11.6%	41/64	64.1%

TABLE 16
BILATERAL - UNCORRECTED VISUAL ACUITY

	NEAR AT 40 CM		INTERMEDIATE AT 80 CM		DISTANCE	
20/20 or better	39/124	31.5%	120/124	96.8%	98/123	79.7%
20/25 or better	90/124	72.6%	122/124	98.4%	113/123	91.9%
20/32 or better	116/124	93.5%	124/124	100%	120/123	97.6%
20/40 or better	122/124	98.4%	124/124	100%	121/123	98.4%
Worse than 20/40	2/124	1.6%	0/124	0%	2/123	1.6%

TABLE 17
BILATERAL - UNCORRECTED VISUAL ACUITY
FOR PATIENTS WITHIN $\pm 0.5D$ OF PLANO IN EACH EYE

	NEAR AT 40 CM		INTERMEDIATE AT 80 CM		DISTANCE	
20/20 or better	17/74	23.0%	NA	NA	67/74	90.5%
20/25 or better	49/74	66.2%	74/74	100%	73/74	98.6%
20/32 or better	72/74	97.3%	74/74	100%	74/74	100%
20/40 or better	74/74	100%	74/74	100%	74/74	100%
Worse than 20/40	0/74	0%	0/74	0%	0/74	0%

TABLE 18
BILATERAL UNCORRECTED VISUAL ACUITY (1 YEAR VERSUS 3 YEAR)

	NEAR AT 40 CM				DISTANCE			
	1 Year		3 Year		1 Year		3 Year	
20/25 or better	90/124	72.6%	36/50	72.0%	113/123	91.9%	46/50	92.0%
20/32 or better	116/124	93.5%	43/50	86.0%	120/123	97.6%	47/50	94.0%
20/40 or better	122/124	98.4%	49/50	98.0%	121/123	98.4%	49/50	98.0%
Worse than 20/40	2/124	1.6%	1/50	2.0%	2/123	1.6%	1/50	2.0%

TABLE 19
BILATERAL DISTANCE CORRECTED NEAR VISUAL ACUITY (1 YEAR VERSUS 3 YEAR)

	1 YEAR		3 YEAR	
20/25 or better	64/124	51.6%	29/50	58.0%
20/32 or better	104/124	83.9%	42/50	84.0%
20/40 or better	124/124	100%	50/50	100%
Worse than 20/40	0/124	0%	0/50	0%

TABLE 20
UNILATERAL - UNCORRECTED VISUAL ACUITY (ALL EYES)

	NEAR AT 40 CM		INTERMEDIATE AT 80 CM		DISTANCE	
20/20 or better	52/368	14.1%	--	--	184/371	49.6%
20/25 or better	161/368	43.8%	--	--	269/371	72.5%
20/32 or better	256/368	69.6%	--	--	311/371	83.8%
20/40 or better	328/368	89.1%	--	--	339/371	91.4%
Worse than 20/40	40/368	10.9%	--	--	32/371	8.6%

TABLE 21
BILATERAL PATIENT SURVEY*
ACTIVITIES WITHOUT SPECTACLES, US BILATERAL SUBJECTS

ACTIVITY	YES N/N (%)	NO N/N (%)
Perform most visual functions	120/128 (93.8%)	8/128 (6.3%)
Read most things	100/129 (77.5%)	29/129 (22.5%)
Go shopping	116/124 (93.5%)	8/124 (6.5%)
Participate in sports	84/87 (96.6%)	3/87 (3.4%)
Attend social gatherings	120/126 (95.2%)	6/126 (4.8%)
Drive	111/121 (91.7%)	10/121 (8.3%)
Read a newspaper	73/128 (57.0%)	55/128 (43.0%)
Sew or do needlework	35/91 (38.5%)	56/91 (61.5%)
Work on a computer	75/93 (80.6%)	18/93 (19.4%)
Do handy work around the house	119/126 (94.4%)	7/126 (5.6%)
Walk	126/129 (97.7%)	3/129 (2.3%)
Shop	117/128 (91.4%)	11/128 (8.6%)
Watch television	120/130 (92.3%)	10/130 (7.7%)

* Self-administered anonymous mail-in survey

TABLE 22
BILATERAL PATIENT SURVEY
DIFFICULTY WITH NIGHT ACTIVITY, US BILATERAL SUBJECTS

	ABSENT N/N (%)	MILD N/N (%)	MODERATE N/N (%)	SEVERE N/N (%)
Night-time glare/flare	74/130 (56.9%)	31/130 (23.8%)	18/130 (13.8%)	74/130 (5.4%)
Night vision (difficulty driving at night)	82/121 (67.8%)	21/121 (17.4%)	14/121 (11.6%)	4/121 (3.3%)
Halos (rings around lights)	80/130 (61.5%)	26/130 (20.0%)	16/130 (12.3%)	8/130 (6.2%)

TABLE 23
BILATERAL PATIENT SURVEY
WEARING SPECTACLES DURING WAKING HOURS AND TO SEE AT NIGHT, US BILATERAL SUBJECTS

WEARING SPECTACLES	N/N (%)
HOW OFTEN DO YOU WEAR SPECTACLES DURING WAKING HOURS?	
I do not wear spectacles	33/128 (25.8%)
I wear spectacles almost none of the time (10%-25%)	61/128 (47.7%)
I wear spectacles some of the time (26%-50%)	20/128 (15.6%)
I wear spectacles most of the time (51%-75%)	8/128 (6.3%)
I wear spectacles all the time or almost all the time (76%-100%)	6/128 (4.7%)
DO YOU WEAR SPECTACLES TO SEE AT NIGHT?	
No	110/130 (84.6%)
Yes	20/130 (15.4%)

TABLE 24
ADVERSE EVENTS REPORTED AT 12 MONTHS


ADVERSE EVENT	CUMULATIVE		FDA GRID	PERSISTENT		FDA GRID
	PRIMARY EYES	ALL EYES		PRIMARY EYES	ALL EYES	
Endophthalmitis	1/324 (0.3%)	1/497 (0.2%)	0.1%	----	----	----
HypHEMA	1/324 (0.3%)	1/497 (0.2%)	2.2%	----	----	----
Hypopyon	0/324	0/497	0.3%	----	----	----
IOL Dislocation	0/324	0/497	0.1%	----	----	----
Cystoid Macular Edema	12/324 (3.7%)	13/497 (2.6%)	3.0%	2/304 (0.7%)	3/450 (0.7%)	0.5%
Pupillary Block	0/324	0/497	0.1%	----	----	----
Retinal Detachment	0/324	0/497	0.3%	----	----	----
Secondary Surgical Reintervention	2/324 (0.6%)	4/497 (0.8%)	0.8%	----	----	----
Corneal Edema	----	----	----	0/298	0/440	0.3%
Iritis	----	----	----	2/298 (0.7%)	3/440 (0.7%)	0.3%
Raised IOP Requiring Treatment	----	----	----	0/304	0/450	0.4%

ASPHERIC INFORMATION

The Trulign AO has prolate aspheric surfaces, similar to Crystalens AO, and is designed to be free of spherical aberration. The image quality of the Crystalens AO is illustrated in the figure below in the form of a modulation transfer function curve.

NOTE: Based on bench testing, the lens models with aspheric surfaces may provide somewhat reduced near acuity compared to the spherical model. No clinical study was performed to verify these findings or to assess the effect of the added aspheric surface on spherical aberration, night-time distance visual acuity, and contrast sensitivity compared to the parent model Crystalens® model AT-45.

NOTE: The image quality of models AT50AO and AT50SE was characterized by measuring modulation transfer function (MTF) in a model eye described in ISO 11979-2 through 3 mm and 4.5 mm lens apertures.



HAPTICS

The plate haptics are 0° +/- 2° from the optic plane and have hinges across the face of the plates adjacent to the optic. Two flexible colored polyimide (Kapton) loops are attached to each distal extremity of the plates (see lens illustrations for overall length per model). The length of the plate is 10.5 mm.

MECHANISM OF ACTION

The Trulign was designed to move in a backward and forward motion along the axis of the eye in response to pressure changes in the vitreous cavity and anterior chamber that result from relaxation and contraction of the ciliary muscle. The exact mechanism of action has not been fully elucidated.

Trulign Toric has axis marks on the anterior surface denoting the flat meridian of the lens. Aligning the axis mark with the post-operative steep corneal meridian allows the lens to correct astigmatism.

DIRECTIONS FOR USE

BAUSCH + LOMB TORIC CALCULATOR

For optimal results, the Bausch + Lomb Toric Calculator will be used to select the appropriate cylinder power of the toric lens. The Bausch + Lomb Toric Calculator will calculate the predicted post-op corneal astigmatism using pre-op keratometry, phaco/insertion incision location and expected magnitude of surgically-induced astigmatism inputs from the Surgeon. The calculator will account for surgically induced astigmatism, incision location and the patient's pre-op corneal astigmatism, and will determine the Toric IOL cylinder power needed and placement orientation in order to best correct a patient's expected post-op corneal astigmatism.

Complete the following steps:

1. Measure patient keratometry and axis
2. Start the Bausch + Lomb Toric Calculator software program
3. Enter the requested information into the calculator program.
4. Press the calculate button.
5. Identify the Toric IOL cylinder power that needs to be implanted.
6. Identify the correct Lens.
7. Print the results.

PLACEMENT OF TRULIGN TORIC

The surgeon must ensure correct placement and orientation of the lens within the eye. All lenses will be oriented along the expected post-op steep meridian of the cornea. The surgeon should keep in mind misalignment of the long axis of the lens with the steep keratometric meridian will reduce its effectiveness by approximately 3% for every 1 degree of misalignment.

The Toric lens is marked with two lines at the edge of the optic that are aligned with the long axis of the lens. Since the preoperative refraction is frequently not accurate or can be influenced by lenticular astigmatism, it is necessary to align the lens with the expected post-op steep axis of the cornea as indicated by the toric calculator rather than use refractive data. For example: 45.00 D at 180, 43.00 D at 90, align the long axis of the Model BL1UT at 180.

MARKING THE CORNEA PRIOR TO SURGERY

NOTE: Use the Trulign Toric Lens Calculator software to determine the appropriate lens cylinder power and axis placement which accounts for both pre-existing corneal astigmatism and the surgically induced astigmatism from the incision (see below).

Immediately prior to surgery the subject's operative eye will be marked to identify the axis of placement while seated at the slit-lamp. The following procedure will be followed.

- Ensure there is adequate corneal anesthesia.
 - Seat the subject at the CS0 slit lamp microscope and ensure the head is erect and straight with no head rotation that could affect the correct orientation of the intended axis placement.
 - Ensure that the patient's pupil is dilated.
 - Direct the subject to look at a distance fixation object visible to the non-operative eye.
 - Using a full height slit that is approximately 0.2mm wide, rotate the lamp housing and use the degree scale to select the approximate axis of placement.
 - With the slit beam indicating the correct axis of placement, mark the eye with the surgeon's preferred method referenced for marking the cornea.
 - After marking the cornea, capture a digital photo to record the axis of placement marks with respect to the reference blood vessels.
1. Prior to implanting, examine the lens package for IOL type, power, and expiration date.
 2. Open the peel pouch and remove the lens from the sterile packaging by pressing and lifting the cover off the plastic lens case (holder). Place the lens in a sterile environment.
 3. Examine the lens thoroughly to ensure particles have not become attached to it, and examine the lens optical surface for other defects.
 4. Position the lower blade of the forceps in the slot of the lens case beneath the lens. A Cumming intraocular lens forceps is recommended. Grasp the lens so that the forceps extends across the *distal hinge* to stabilize the *leading plate haptic*. **Do not grasp the lens by the haptics.**
 5. Remove the lens in its position for implantation with a single grasp.

INSERTION DEVICE DETAILS

6. The Crystalsert™ delivery system may be used to inject the Trulign. A cohesive viscoelastic should be used for lubrication of the injector when inserting the IOL. The IOL should be injected within three minutes after loading. Refer to the instructions for use supplied with the injector. See <http://www.crystalens.com> for further details on the use of the injector with the Trulign.

INSERTION BY FORCEPS

7. Advance the forceps to place the *leading plate haptic* of the lens into the distal capsular bag, which should be completely filled with a cohesive viscoelastic.
8. The round knob on the loop of the leading haptic should be on the right to ensure that the hinge's "open" side is "right side up" and is facing the anterior part of the eye on implantation.
9. With a second instrument, hold the proximal *polyimide* loop to maintain the position of the lens in the capsular bag as the implantation forceps are withdrawn from the eye.
10. Regrasp at the tip of the *trailing plate haptic* with the implantation forceps.
11. As you advance the *trailing plate haptic* into the anterior chamber, the polyimide loops will bend back on themselves as they traverse the small incision. Advance the leading plate up towards the cornea. *This will cause the leading plate haptic to bend to a right angle deep into the bag.*
12. Maintain your grasp at the tip of the *trailing plate haptic*. Tuck the polyimide loops, one by one, into the capsular bag. **Do not release the tip until the loops are in the bag.**
13. Release and withdraw the forceps. The lens will self-center.

NOTE: The lens may pick up an electrostatic charge upon opening the package. The lens should be carefully examined to ensure that particles have not been attracted to its surface.

LENS POWER CALCULATIONS

The surgeon should determine preoperatively the power of the lens to be implanted by using either immersion or IOL Master biometry and manual keratometry. Lens power calculation methods are described in the following references:

- Holladay JT et al. A Three Part System for Refining Intraocular Lens Power Calculations. *J Cataract Surg* 14, January 1988.
- Retzlaff JA et al. Development of the SRK/T intraocular lens implant power calculation formula. *J Cataract Refract Surg* 16, May 1990.
- Hoffer KJ. The Hoffer Q Formula. A comparison of theoretical and regression formulas. *J Cataract Refract Surg* 19, November 1993.

NOTE: The Surgeon Factor, 'A' Constant and ACD values, which are located on the outside of the package, are estimates only. It is recommended that the surgeon determine his/her own values based on their individual clinical experience. Surgeons requiring additional information on lens power calculation may contact Bausch + Lomb.

RECOMMENDATIONS FOR MAXIMIZING PATIENT OUTCOMES

- IOL Master or manual keratometry, immersion biometry or interferometry is strongly recommended to obtain optimum patient outcomes.
- The first eye implant should be targeted for between -0.25 and -0.50 diopter and the second eye implant targeted for plano. In any case, the outcome of the second eye implant should be determined based on the outcome of the first eye.
- A waiting period of two weeks between the first and second eye is recommended in order to accurately determine the lens power for the second eye.
- Incision width should be 3.5 to 3.7 mm but no larger than 4 mm and should be at least 2.5 mm long. The paracentesis should be approximately 1.0 to 1.5 mm in width and approximately 2.0 mm long.
- The capsulorhexis should be round (5.5 to 6.0 mm) with the anterior capsule covering the plate haptics. If the capsulorhexis is oval, then the lens should be rotated to ensure maximum coverage of the plate haptics.
- Meticulous cortical clean-up should be performed and the lens rotated at least 90° to dislodge any hidden or trapped cortex.
- Patients should be kept on a tapering course of anti-inflammatory agents for a minimum of 4 weeks.

PATIENT REGISTRATION INSTRUCTIONS AND REPORTING REGISTRATION

Each patient who receives a Trulign must be registered with Bausch + Lomb at the time of lens implantation.

Registration is accomplished by completing the Implant Registration Card that is enclosed in the lens package and mailing it to Bausch + Lomb. Patient registration is essential and will assist Bausch + Lomb in responding to adverse reaction reports and/or potentially sight-threatening complications. An implant identification card is supplied in the lens package and must be given to the patient.

REPORTING

Adverse Reactions and/or potentially sight-threatening complications that may reasonably be regarded as lens related and that were not previously expected in nature, severity or degree of incidence should be reported to Bausch + Lomb at 866-393-6642 (USA). This information is being requested from all surgeons in order to document potential long-term effects of intraocular lens implantation.

HOW SUPPLIED

The contents of the inner and outer peel pouches are sterile unless the packages are damaged or opened. The intraocular lenses are moist heat sterilized and supplied in a lens case within a double aseptic transfer peel pouch.

EXPIRATION DATE

Sterility is guaranteed unless the sterile pouch is damaged or opened. In addition, there is a sterility expiration date that is clearly indicated on the outside of the package. The lens should not be used after the indicated date.

RETURNED LENS POLICY

Please contact your local Bausch + Lomb office regarding lens exchange.

BIBLIOGRAPHY

1. Boettner, EA and Wolter JR 1962. Transmission of the ocular media. *Invest Ophthalmol* 1: 776-783.
2. Busacca, A. La Physiologie Du Muscle Ciliaire Etudiee Par La Gonioscopie. *Annales D'Oculistique* 1955; 1-21.
3. Coleman J. On the hydraulic suspension theory of accommodation. *Trans Am Ophth Soc* 1986; 846-868.
4. Colin, J. Clinical results of implanting a silicone haptic-anchor-plate intraocular lens. *J Cataract Refract Surg*, 1996;2:1286-1290.
5. Cumming JS et al. Clinical evaluation of the Model AT-45 silicone accommodating intraocular lens. *Ophthalmology* 2001;108:2005-2010.
6. Cumming JS, Ritter J. The Measurement of Vitreous Cavity Length and its Comparison Pre- and Postoperatively. *Eur J Implant Ref Surg* 1994;6:261-272.
7. Fisher R. The ciliary body in accommodation. *Tran Ophthalmol Soc UK* 1986;105:208-219.
8. Girard LJ et al. Complications of the Simcoe Flexible Loop Phacoprosthesis in the anterior chamber. *Ophthalmic Surg* 14(4)
9. Glasser A and Kaufman PL. The mechanism of accommodation in primates. *Ophthalmol* 1999;106: 863-872.
10. Kammann J. Vitreous-stabilizing, single-piece, mini-loop, plate-haptic silicone intraocular lens. *J Cataract Refract Surg* 1998;24:98-106.
11. Thornton S. Accommodation in pseudophakia. *Color Atlas of Lens Implantation*. 1991;159-162.
12. Willis DA, Stewart RH, Kimbrough RL. Pupillary block associated with posterior chamber lenses. *Ophthalmic Surg* 1985; 16:108-9.

FIG. 1




FIG. 2





FIGURE 1 MODEL BL1AT/BL1UT/AT50T

FIGURE 2 MODEL BL2AT/BL2UT /AT52T

FIGURE 3 – SPECTRAL TRANSMITTANCE WITH MODEL(S) AT50T (REPRESENTATIVE OF AT50T, AT52T, BL1AT, AND BL2AT), HUMAN CRYSTALLINE LENS AND, BL1UT (REPRESENTATIVE OF BL1UT AND BL2UT)



NOTES:

Spectral Transmittance Curve for BL1UT/BL2UT (20.0D equivalent) has a 10% UV cut-off at 400 nm

Spectral Transmittance Curve for AT50T/AT52T (20.0 D equivalent) has a 10% UV cutoff at 350nm

Spectral Transmittance Curve Corresponding to 53 year-old Phakic Eye (see Bibliography reference #1)

SYMBOLS

ENGLISH



Manufacturer



Do not reuse



YYYY-MM



Date of Manufacture (YYYY-MM)



Caution: Consult Instructions for Use



Sterilized Using Steam or Dry Heat



45°C (113°F)
Max.

Upper Limit of Temperature



Authorized representative in the European community



Member Green Dot Scheme



Do not resterilize



Caution: Federal (U.S.A.) law restricts this device to sale by or on the order of a licensed practitioner



Do not use if the package is damaged

DRAFT



Bausch & Lomb Incorporated
Aliso Viejo, CA 92656 USA



Bausch & Lomb Incorporated
106 London Road
Kingston-upon-Thames, KT2 6TN, UK

Manufacturing site:

Bausch & Lomb Incorporated
10574 Acacia Street, Suite D-1, Rancho Cucamonga, CA 91730 USA

™/® denote trademarks of Bausch & Lomb Incorporated.
All other brand/product names are trademarks of their respective owners.
© Bausch & Lomb Incorporated. All rights reserved.

4104200
14

13-Feb-2013 Rev A



DO NOT REUSE



45°C (113°F)
Max.

